share_log

S-3: Registration statement for specified transactions by certain issuers

S-3: Registration statement for specified transactions by certain issuers

S-3:特定交易註冊聲明
美股SEC公告 ·  09/10 00:40
牛牛AI助理已提取核心訊息
Aclarion, Inc., a healthcare technology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 6, 2024. The filing indicates Aclarion's intent to offer and sell securities, including common stock, preferred stock, warrants, subscription rights, debt securities, and units, up to a total gross proceeds of $50,000,000. The securities may be offered from time to time in one or more series, and the proceeds are intended for market development, clinical evidence, product development, general administration support, and other corporate purposes. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has also detailed its indemnification policy for directors and officers, stating that it will provide mandatory indemnification to the fullest extent permitted by law. The registration statement includes various legal and financial documents, such as the company's bylaws, certificate of incorporation, and financial statements audited by Haynie & Company and CohnReznick LLP.
Aclarion, Inc., a healthcare technology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 6, 2024. The filing indicates Aclarion's intent to offer and sell securities, including common stock, preferred stock, warrants, subscription rights, debt securities, and units, up to a total gross proceeds of $50,000,000. The securities may be offered from time to time in one or more series, and the proceeds are intended for market development, clinical evidence, product development, general administration support, and other corporate purposes. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has also detailed its indemnification policy for directors and officers, stating that it will provide mandatory indemnification to the fullest extent permitted by law. The registration statement includes various legal and financial documents, such as the company's bylaws, certificate of incorporation, and financial statements audited by Haynie & Company and CohnReznick LLP.
醫療科技公司Aclarion, Inc.於2024年9月6日向美國證券交易委員會(SEC)提交了一份S-3表格註冊聲明。該提交表明Aclarion打算髮行和出售證券,包括普通股、優先股、認股權證、認購權、債券和單位,總毛收入不超過5000萬美元。證券可能在不同時期以一種或多種系列方式發行,收益將用於市場開發、臨床證據、產品開發、一般行政支持和其他公司目的。Aclarion的普通股股票在納斯達克資本市場上以代碼'ACON'進行交易。該公司還詳細說明了其爲董事和高管提供的擔保政策,表示將根據法律規定提供強制性擔保。註冊聲明包括各種法律和財務文件,例如公司章程、公司註冊證明和由Haynie & Company和CohnReznick LLP審計的財務報表。
醫療科技公司Aclarion, Inc.於2024年9月6日向美國證券交易委員會(SEC)提交了一份S-3表格註冊聲明。該提交表明Aclarion打算髮行和出售證券,包括普通股、優先股、認股權證、認購權、債券和單位,總毛收入不超過5000萬美元。證券可能在不同時期以一種或多種系列方式發行,收益將用於市場開發、臨床證據、產品開發、一般行政支持和其他公司目的。Aclarion的普通股股票在納斯達克資本市場上以代碼'ACON'進行交易。該公司還詳細說明了其爲董事和高管提供的擔保政策,表示將根據法律規定提供強制性擔保。註冊聲明包括各種法律和財務文件,例如公司章程、公司註冊證明和由Haynie & Company和CohnReznick LLP審計的財務報表。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。